

Supplementary Table1. Patients' characteristics including HbA1c and eGFR at baseline among T2D using SGLT2 inhibitors

	Overall (n=16,754)		Hypoglycemia (+) (n=30)		Hypoglycemia (-) (n=16,724)		p value
	Mean ±S.D	n(%)	Mean ±S.D	n(%)	Mean ±S.D	n(%)	
Gender							
Male		10,941 (65.3)		18 (60.0)		10,923 (65.3)	0.541
Female		5,813 (34.7)		12 (40.0)		5,801 (34.7)	
Age (years)							
	61.9±13.3		70.7±11.7		61.8±13.3		<0.001
<25		81 (0.5)		0		81 (0.5)	<0.001
25-<44		1,781 (10.6)		0		1,781 (10.6)	
45-<64		7,006 (41.8)		10 (33.3)		6,996 (41.8)	
≥65		7,886 (47.1)		20 (66.7)		7,866 (47.0)	
BMI (kg/m²)							
	27.4±5.9		25.2±4.6		27.4±5.9		0.046
<25		10,938 (65.3)		16 (53.3)		10,922 (65.3)	0.169
≥25		5,816 (34.7)		14 (46.7)		5,802 (34.7)	
HbA1c (%)							
	7.49±1.30		7.03±1.2		7.50±1.3		0.027
<7.0		6,354 (37.9)		13 (43.3)		6,341 (37.9)	0.541
≥7.0		10,400 (62.1)		17 (56.7)		10,383 (62.1)	
eGFR (mL/min)							
	71.6±26.3		55.2±33.2		72.6±26.2		<0.001
≥60		11,417 (68.1)		11 (36.7)		11,406 (68.2)	<0.001

30-59	4,612 (27.5)	12 (40.0)	4,600 (27.5)	
<30	725 (4.3)	7 (23.3)	718 (4.3)	
Baseline use of other anti-diabetic medications				
α -GI	2,282 (13.6)	6 (20.0)	2,276 (13.6)	0.308
DPP-4 inhibitors	9,668 (57.7)	19 (63.3)	9,649 (57.7)	0.532
Glinides	929 (5.5)	5 (16.7)	924 (5.5)	0.008
GLP-1 agonists	654 (3.9)	2 (6.7)	652 (3.9)	0.434
Insulin	3,550 (45.7)	17 (56.7)	3,533 (21.1)	<0.001
Metformin	7,389 (44.1)	7 (23.3)	7,382 (44.1)	0.022
Sulfonylureas	3,895 (23.2)	9 (30.0)	3,886 (23.2)	0.381
Thiazolidinedilones	1,371 (8.2)	4 (13.3)	1,367 (8.2)	0.303

HbA1c, glycohemoglobin; eGFR, estimated glomerular filtration rate; T2D, type 2 diabetes; SGLT2, sodium-glucose co-transporter 2; hypoglycemia (+), patients with hypoglycemic events; hypoglycemia (-), patients without hypoglycemic events; SD, standard deviation; BMI, body-mass index; α -GI, alpha-glucosidase inhibitor; DPP-4, dipeptidyl peptidase-4; GLP-1, glucagon-like peptide-1. P values were calculated for differences between patients with and without hypoglycemic events.